IP Library Granted Patent US 10,624,940
Granted Patent B2
US 10,624,940 · App. 16/359,579 · Granted Apr 21, 2020

Pharmaceutical composition and method of manufacturing

Inventor: Gary J. Speier (Eden Prairie, MN)
Assignee: CURE PHARMACEUTICAL HOLDING CORP.
A61K36/185A61K9/006A61K9/7023A61K31/05A61K31/352A61K36/00B01D11/0407A61K2236/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,940
App. No.
16/359,579
Granted
Apr 21, 2020
Kind
B2
Abstract

The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis . The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis , as well as methods of medical treatment that include administering the pharmaceutical dosage forms.

Claims (67)

1. A process for obtaining a first and second concentrate of Cannabis sativa, Cannabis indica , or a combination thereof, the process comprising:

(a) contacting Cannabis sativa, Cannabis indica , or a combination thereof with a supercritical fluid solvent system comprising carbon dioxide, at a pressure of about 750 to about 3,000 psi, and at a temperature of about −20° C. to about 70° C., to provide an extract of Cannabis sativa, Cannabis indica , or a combination thereof; and

(b) removing the supercritical fluid solvent system comprising carbon dioxide from the extract of Cannabis sativa, Cannabis indica , or a combination thereof;

wherein,

the contacting in (a) of the Cannabis sativa, Cannabis indica , or a combination thereof with the supercritical fluid solvent system comprising carbon dioxide and the removing in (b) of the supercritical fluid solvent system comprising carbon dioxide, is carried out two or more times, such that the process is a fractional supercritical fluid extraction comprising carbon dioxide;

the first fractional supercritical fluid extraction comprising carbon dioxide is carried out such that contacting of the Cannabis sativa, Cannabis indica , or a combination thereof provides a first concentrate; and the second fractional supercritical fluid extraction comprising carbon dioxide is carried out such that contacting of the Cannabis sativa, Cannabis indica , or a combination thereof provides a second concentrate;

if the first concentrate is enriched with tetrahydrocannabinol then the second concentrate is enriched with cannabidiol;

if the first concentrate is enriched with cannabidiol then the second concentrate is enriched with tetrahydrocannabinol;

each of the first and the second fractional supercritical fluid extractions comprising carbon dioxide are carried out at a pressure of about 750 to about 3,000 psi, a temperature of about −20° C. to about 70° C., and for a period of time of about 1 to about 8 hours, provided the first and the second fractional supercritical fluid extractions are carried out: (i) at a different temperature, (ii) at a different pressure, (iii) with a different solvent system comprising carbon dioxide, or (iv) a combination thereof; and

one of the fractional supercritical fluid extractions comprising carbon dioxide is carried out at a temperature of at least 30° C.

2. The process of claim 1 , wherein the first fractional supercritical fluid extraction is carried out in a solvent system that comprises carbon dioxide and a second solvent selected from the group consisting of hydrogen, neon, nitrogen, argon, methane, ethane, propane, ammonia, water, xenon, methanol, ethanol, 1-propanol, 2-propanol, 1-hexanol, 2-methoxy ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, methylene chloride, dichloroethane, chloroform, ethyl acetate, propylene carbonate, N,N-dimethylaceamide, dimethyl sulfoxide, formic acid, carbon disulfide, acetone, toluene, hexanes, pentanes, trifluoromethane, nitrous oxide, sulfur hexafluroide, butane, isobutane, ethyl ether, benzotrifluoride, p-(chlorophenyl)trifluoromethane, chlorofluorocarbon, hydrofluorocarbon, and combinations thereof.

3. The process of claim 1 , wherein relative to the Cannabis sativa, Cannabis indica , or a combination thereof in step (a), the concentrate enriched with tetrahydrocannabinols contains at least about a 10% higher concentration of tetrahydrocannabinols.

4. The process of claim 1 , wherein the second fractional supercritical fluid extraction is carried out in a solvent system that comprises carbon dioxide and a second solvent selected from the group consisting of hydrogen, neon, nitrogen, argon, methane, ethane, propane, ammonia, water, xenon, methanol, ethanol, 1-propanol, 2-propanol, 1-hexanol, 2-methoxy ethanol, tetrahydrofuran, 1,4-dioxane, acetonitrile, methylene chloride, dichloroethane, chloroform, ethyl acetate, propylene carbonate, N,N-dimethylaceamide, dimethyl sulfoxide, formic acid, carbon disulfide, acetone, toluene, hexanes, pentanes, trifluoromethane, nitrous oxide, sulfur hexafluroide, butane, isobutane, ethyl ether, benzotrifluoride, p-(chlorophenyl)trifluoromethane, chlorofluorocarbon, hydrofluorocarbon, and combinations thereof.

5. The process of claim 1 , wherein each fractional supercritical fluid extraction is carried out with a different supercritical fluid solvent system.

6. The process of claim 1 , wherein each fractional supercritical fluid extraction is carried out with a different supercritical fluid solvent system comprising carbon dioxide, wherein each different solvent system comprising carbon dioxide is selected from the group consisting of polar aprotic, polar protic, nonpolar aprotic, and nonpolar protic.

7. The process of claim 1 , wherein relative to the Cannabis sativa, Cannabis indica , or a combination thereof in step (a), the Cannabis concentrate enriched with cannabidiol contains at least about a 10% higher concentration of cannabidiol.

8. The process of claim 1 , further comprising purifying the first concentrate of Cannabis sativa, Cannabis indica , or a combination thereof by employing at least one of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, and sublimation.

9. The process of claim 1 , further comprising purifying the second concentrate of Cannabis sativa, Cannabis indica , or a combination thereof by employing at least one of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, and sublimation.

10. The process of claim 1 , wherein relative to the Cannabis sativa, Cannabis indica , or a combination thereof in step (a), the first concentrate contains a lower concentration of a component selected from the group consisting of:

(i) cannabinol,

(ii) alkaloids,

(iii) terpenes,

(iv) terpenoids,

(v) cannabinoid acids,

(vi) hemp oil, and

(vii) combinations thereof.

11. The process of claim 1 , wherein relative to the Cannabis sativa, Cannabis indica , or a combination thereof in step (a), the first concentrate contains at least a 10% lower concentration of a component selected from the group consisting of:

(i) cannabinol,

(ii) alkaloids,

(iii) terpenes,

(iv) terpenoids,

(v) cannabinoid acids,

(vi) hemp oil, and

(vii) combinations thereof.

12. The process of claim 1 , wherein relative to the Cannabis sativa, Cannabis indica , or a combination thereof in step (a), the second concentrate contains a lower concentration of a component selected from the group consisting of:

(i) cannabinol,

(ii) alkaloids,

(iii) terpenes,

(iv) terpenoids,

(v) cannabinoid acids,

(vi) hemp oil, and

(vii) combinations thereof.

13. The process of claim 1 , wherein relative to the Cannabis sativa, Cannabis indica , or a combination thereof in step (a), the second concentrate contains at least a 10% lower concentration of a component selected from the group consisting of:

(i) cannabinol,

(ii) alkaloids,

(iii) terpenes,

(iv) terpenoids,

(v) cannabinoid acids,

(vi) hemp oil, and

(vii) combinations thereof.

14. The process of claim 1 , wherein the first fractional supercritical fluid extraction comprising carbon dioxide is carried out with carbon dioxide as the only solvent.

15. The process of claim 1 , wherein the second fractional supercritical fluid extraction comprising carbon dioxide is carried out with carbon dioxide as the only solvent.

16. The process of claim 1 , wherein the concentrate enriched with tetrahydrocannabinol comprises at least about 90 wt. % tetrahydrocannabinol.

17. The process of claim 1 , wherein the concentrate enriched with cannabidiol comprises at least about 90 wt. % cannabidiol.

18. A process for obtaining a first and second concentrate of Cannabis sativa, Cannabis indica , or a combination thereof, the process comprising:

(a) contacting Cannabis sativa, Cannabis indica , or a combination thereof with a supercritical fluid solvent system comprising carbon dioxide, at a pressure of about 750 to about 3,000 psi, and at a temperature of about −20° C. to about 70° C., to provide an extract of Cannabis sativa, Cannabis indica , or a combination thereof; and

(b) removing the supercritical fluid solvent system comprising carbon dioxide from the extract of Cannabis sativa, Cannabis indica , or a combination thereof;

wherein,

the contacting in (a) of the Cannabis sativa, Cannabis indica , or a combination thereof with the supercritical fluid solvent system comprising carbon dioxide and the removing in (b) of the supercritical fluid solvent system comprising carbon dioxide, is carried out two or more times, such that the process is a fractional supercritical fluid extraction comprising carbon dioxide;

the first fractional supercritical fluid extraction comprising carbon dioxide is carried out such that contacting of the Cannabis sativa, Cannabis indica , or a combination thereof provides a first concentrate; and the second fractional supercritical fluid extraction comprising carbon dioxide is carried out such that contacting of the Cannabis sativa, Cannabis indica , or a combination thereof provides a second concentrate;

if the first concentrate is enriched with tetrahydrocannabinol then the second concentrate is enriched with cannabidiol;

if the first concentrate is enriched with cannabidiol then the second concentrate is enriched with tetrahydrocannabinol;

each of the first and the second fractional supercritical fluid extractions comprising carbon dioxide are carried out at a pressure of about 750 to about 3,000 psi, a temperature of about −20° C. to about 70° C., and for a period of time of about 1 to about 8 hours, provided the first and the second fractional supercritical fluid extractions are carried out: (i) at a different temperature, (ii) at a different pressure, (iii) with a different solvent system comprising carbon dioxide, or (iv) a combination thereof;

in step (a), each of the first concentrate and the second concentrate independently contain at least a 10% lower concentration of a component selected from the group consisting of: (i) cannabinol, (ii) alkaloids, (iii) terpenes, (iv) terpenoids, (v) cannabinoid acids, (vi) hemp oil, and (vii) combinations thereof; and

one of the fractional supercritical fluid extractions comprising carbon dioxide is carried out at a temperature of at least 30° C.

19. The process of claim 18 , wherein the first fractional supercritical fluid extraction comprising carbon dioxide is carried out with carbon dioxide as the only solvent; and the second fractional supercritical fluid extraction comprising carbon dioxide is carried out with carbon dioxide as the only solvent.

20. The process of claim 18 , wherein the concentrate enriched with tetrahydrocannabinol comprises at least about 90 wt. % tetrahydrocannabinol and the concentrate enriched with cannabidiol comprises at least about 90 wt. % cannabidiol.

Assignments (3)
SECURITY INTEREST Recorded Oct 18, 2024
From: AVENIR WELLNESS SOLUTIONS, INC.
To: SINDERBRAND LAW GROUP, PC
Reel/Frame 068937/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2023
From: AVENIR WELLNESS SOLUTIONS, INC. F/K/A CURE PHARMACEUTICAL HOLDING CORPORATION
To: AVENIR WELLNESS SOLUTIONS, INC.
Reel/Frame 063663/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2020
From: SPEIER, GARY J.
To: CURE PHARMACEUTICAL HOLDING CORP.
Reel/Frame 052048/0179 →
Continuity (5)
Continuation 14934940 · Nov 6, 2015
Continuation 14723980 · May 28, 2015
Continuation In Part 14694303 · Apr 23, 2015
Continuation 14255296 · Apr 17, 2014
Related Publication 20190209633A1 · Jul 11, 2019
Cited By (2)
US 12,329,854 US 12,383,494